Welcome to our dedicated page for Petvivo Hldgs SEC filings (Ticker: PETV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PetVivo Holdings filings document material events for a Nevada corporation operating through PetVivo Animal Health and PetVivo AI. Recent Form 8-K reports cover subscription agreements, unregistered equity sales, restricted common stock, warrants, unit issuances, and Regulation D exemptions tied to private financing activity.
The filing record also includes Regulation FD investor-presentation exhibits and governance disclosures under Item 5.02, including director resignations and changes in board size. These documents provide formal disclosure around the company’s capital structure, warrant terms, board composition, and public-company reporting status as an emerging growth company.
PetVivo Holdings (PETV) director reported multiple stock grants. On 10/01/2025, the director acquired 14,935 shares of restricted common stock at $1.19 as compensation for prior consulting services. On 10/10/2025, additional restricted stock grants were recorded: 12,500 shares at $1.28 for quarterly Board service vesting, 50,000 shares at $1.28 tied to a warrant exercise with a $25,000 payment to the company, and 100,000 shares at $1.28 tied to a warrant exercise with a $50,000 payment to the company. Following these transactions, beneficial ownership stood at 311,807 shares, held directly.
PetVivo Holdings (PETV) reported a Form 4 for director Robert Rudelius. On 10/10/2025, he acquired 12,500 shares of common stock at $1.28 as part of an annual 50,000 restricted-share board compensation grant that vests in four equal quarterly installments. Following the transaction, he beneficially owned 314,369 shares directly and 21,000 shares indirectly via a corporation.
PetVivo Holdings (PETV) reported a Form 4 showing Director Joseph Jasper acquired 12,500 restricted common shares at $1.28 on 10/10/2025. The transaction reflects the first quarterly vesting from an annual board compensation grant of 50,000 shares, vesting in four equal installments of 12,500 each.
Following the transaction, Jasper beneficially owned 100,159 shares directly, plus 2,000 shares indirectly held by his spouse.
PetVivo Holdings (PETV) disclosed a Form 4 for a director on 10/10/2025, reporting the acquisition of 12,500 shares of common stock at $1.28 per share. Following the transaction, the director beneficially owns 73,661 shares directly.
The filing notes this is part of an aggregate annual grant of 50,000 restricted shares for Board service, vesting in four equal installments of 12,500 shares at the beginning of each quarter.
PetVivo Holdings, Inc. converted outstanding shareholder debt into equity. Effective as of September 30, 2025, four shareholders holding fourteen promissory notes with an aggregate outstanding amount of $2,018,155, including $1,850,000 of principal and $168,155 of accrued interest, agreed to convert their notes into 3,669,806 shares of PetVivo common stock. The effective conversion prices ranged from $0.50 to $0.75 per share, and the notes were fully converted, treated as paid in full, and cancelled once the shares were issued.
The shares issued are restricted securities, relying on an exemption from registration under Section 4(a)(2) of the Securities Act. The lenders represented that they are accredited investors acquiring the shares for investment, and the stock certificates bear a legend stating that the securities are restricted and cannot be sold or transferred without registration or an applicable exemption.
PetVivo Holdings, Inc. reporting person John Lai, who serves as Chief Executive Officer and a director, reported a non‑derivative acquisition on 09/18/2025. The filing shows a grant of 84,375 shares of common stock at a price of $0.76 to a corporation owned by the reporting person as compensation for past performance, reflecting conversion of a past accrued bonus into common stock. Following the transaction, the reporting person (indirectly) beneficially owned 2,020,710 shares. The Form 4 is signed by John Lai on 09/22/2025. The filing indicates the award was issued as compensation rather than a market purchase.
Garry Lowenthal, Chief Financial Officer of PetVivo Holdings, Inc., received a grant of restricted common stock on 09/18/2025 as compensation for past performance. The grant consisted of 79,375 shares at a stated price of $0.76 and was issued to a corporation owned by Mr. Lowenthal. After the reported transaction, the reporting persons indirect beneficial ownership totaled 592,967 shares. The Form 4 indicates this was a non-derivative award recorded as an acquisition and identifies the grant as compensation rather than a market purchase.